App-Based therapy aims to curb Self-Harm in teens
NCT ID NCT07683234
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether a smartphone app, based on proven talk therapies, can help adolescents aged 12–25 who engage in non-suicidal self-injury (NSSI). Participants use the app for 8 weeks, completing short modules on emotion regulation, distress tolerance, and mindfulness, plus daily check-ins on mood and urges. The goal is to see if the app, added to usual care, reduces self-harm behaviors and depressive symptoms more than usual care alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- digital psychotherapy (smartphone app based on CBT and DBT)
- What this could lead to
- If effective, this app could provide a scalable, accessible treatment option for teens who self-harm, reducing the behavior and improving emotional regulation.
- What could go wrong
- This is an early-stage trial with 110 participants, so results may not generalize. The app is self-guided, so adherence and engagement could vary, and it may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 25 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Non-Suicidal Self-Injury (NSSI) according to DSM-5, confirmed by two psychiatrists with senior professional titles. * Adolescents aged 12-25 years, any gender. * Willing to participate voluntarily and with good insight. Exclusion Criteria: * Presence of severe mental disorders (e.g., schizophrenia, schizoaffective disorder, substance use disorder, intellectual disability). * Major central nervous system diseases (e.g., history of head trauma or infection, intracranial tumor, cerebrovascular disease, epilepsy). * History of major physical diseases (e.g., malignancy, myocardial infarction, liver or kidney dysfunction). * History of abuse of sedative-hypnotics, alcohol, or other psychoactive substances. * History of suicide attempt, current high suicide risk, or current suicidal behavior/ideation. * Pregnancy or breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-suicidal self-injury (NSSI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.